Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.
Department of Medicine, University of Florida , Gainesville, Florida , USA.
Andrew R
AR
Kolarich
Brent A
BA
Reynolds
Coy D
CD
Heldermon
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D020300:Intracranial Hemorrhages / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000556:secondary; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine